Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nemtabrutinib on Digoxin Pharmacokinetics
NCT06625827Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of nemtabrutinib in B-cell malignancy (2 arms), sponsored by Merck & Co. Primary endpoint: Area under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Digoxin. Started Nov 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT06625827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625827.